FAS and ovarian carcinoma: Knockdown of HDAC1 and pharmacological inhibition of HDAC enzymatic activity significantly increased FAS expression in resistant cells, suggesting that particularly histone modifications may contribute to the loss of FAS expression in cisplatin resistant ovarian cancer cells, and that enhancement of FAS expression may increase tumor cell sensitivity to immune cells.